Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer

Barth, Rolf F; H Vicente, MGraca; Harling, Otto K; Kiger, WS; Riley, Kent J; Binns, Peter J; Wagner, Franz M; Suzuki, Minoru; Aihara, Teruhito; Kato, Itsuro; Kawabata, Shinji

doi:10.1186/1748-717X-7-146

Radiation Oncology

Table 2 BNCT clinical trials in the United States and Europe using epithermal neutron beams for patients with brain tumors

From: Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer

Medical institution	Neutron source	Treatment dates	Tumor type & No. of patients^a	Boron compound & treatment^b	Clinical outcome^c	Ref.
Brookhaven National Laboratory, Upton, NY, USA	Brookhaven Medical Research Reactor, BNL, Upton, NY, USA	1994-1999	GBM 53	BPA 250–330 mg/kg in 2 h	MeST: 12.8 mos.	[53, 79, 80, 82]
					2 y OS: 9.4%
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA	MIT Research Reactor, Massachusetts Institute of Technology, Cambridge, USA	1996-1999	20 GBM	BPA 250–350 mg/kg in 1.5 h	MeST: 11.1 mos (n = 18)	[53, 59, 81]
			2 IC MM		2 y OS: 12%
		2002-2003	6 GBM	BPA 14 g/m² in 1.5 h	NA	[61]
Universitätsklinikum Essen, Essen Germany	High Flux Reactor, JRC Petten, The Netherlands	1997-2002	26 GBM	BSH 100 mg/kg in 1.7 h	MeST: 10.4-13.2 mos.	[83, 84]
		2004-2006	4 IC MM (>20 IC mets ea.)	BPA 14 g/m² in 1.5 h	OS: < 3 mos.	[85]
Helsinki University Central Hospital, Helsinki, Finland	FiR-1, VTT Technical Research Centre, Espoo, Finland	1999-2001	30 GBM	BPA 290–500 mg/kg in 2 h	MeST: 11.0-21.9 mos.	[86, 87]
		2001-2008	20 rGBM	BPA 290–450 mg/kg in 2 h	MeST: 7 mos. post BNCT	[88]
			2 rAA		1 y OS: 36%
					2 y OS: 0%
Faculty Hospital of Charles University, Prague, Czech Republic	LVR-15 Reactor, Nuclear Research Institute Rez, Czech Republic	2000-2002	5 GBM	BSH 100 mg/kg in 1 h	NA	[89]
Nyköping Hospital, Nyköping, Sweden	R2-0 Reactor, Studsvik Medical, Nyköping, Sweden	2001-2003	29 GBM	BPA 900 mg/kg in 6 h	MeST: 17.7 mos.	[90–93]
					2 y OS: 14%
		2003-2004	1 rMMng	BPA 900 mg/kg in 6 h	OS: 32, 26+ mos. post BNCT	[94]
			1 rMC
		2001-2005	12 rGBM	BPA 900 mg/kg in 6 h	MeST: 8.7 mos. post BNCT	[95]

^aIncluding other disease sites and patients treated off-protocol, the total number of patients treated at some reactors is much greater than reported here, for FiR-1, ~260, for KURR, >107, and for JRR-4, >200 patients. ^bTreatment is indicated only in cases when it is not solely external beam BNCT. ^cA range of survival is given in some cases to summarize survival reported for different cohorts.
Abbreviations: r recurrent, GBM glioblastoma multiforme, IC MM intracranial metastatic melanoma, AA anaplastic astrocytoma, MMng malignant meningioma, MC mesenchymal chondrosarcoma, AOA anaplastic oligoastrocytoma, MRM meningioma related malignancy, IO-BNCT intraoperative BNCT, XRT external beam radiation therapy (photons), MeST median survival time, 2 y OS 2 year overall survival, RI radiographic improvement, NA not available.

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com